Unione Europea - italiano - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocitopenia - antiemorragici - doptelet è indicato per il trattamento della trombocitopenia grave, in pazienti adulti con malattia cronica di fegato che sono in programma di sottoporsi a una procedura invasiva. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. corticosteroidi, immunoglobuline).

Unione Europea - italiano - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).

Unione Europea - italiano - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - emoglobinuria, parossistica - immunosoppressori - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Unione Europea - italiano - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - blocco neuromuscolare - tutti gli altri prodotti terapeutici - inversione del blocco neuromuscolare indotto da rocuronio o vecuronio. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.